The Evolving Understanding and Approach to Residual Cardiovascular Risk Management

被引：113

作者：

Dhindsa, Devinder S. ^{[1
]}

Sandesara, Pratik B. ^{[1
]}

Shapiro, Michael D. ^{[2
]}

Wong, Nathan D. ^{[3
]}

机构：

[1] Emory Clin Cardiovasc Res Inst, Dept Med, Div Cardiol, Atlanta, GA 30322 USA

[2] Wake Forest Baptist Med Ctr, Ctr Prevent Cardiovasc Dis, Sect Cardiovasc Med, Winston Salem, NC USA

[3] Univ Calif Irvine, Div Cardiol, Heart Dis Prevent Program, Irvine, CA USA

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2020年 / 7卷

关键词：

residual risk; secondary prevention; primary prevention; inflammation; cardiovascular risk factors; cardiovascular disease; atherosclerosis; metabolic syndrome; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; ALL-CAUSE MORTALITY; PHOSPHOLIPASE A(2); HDL CHOLESTEROL; EFFLUX CAPACITY; SECONDARY PREVENTION; CLONAL HEMATOPOIESIS; ENDOTHELIAL FUNCTION; REMNANT CHOLESTEROL;

D O I：

10.3389/fcvm.2020.00088

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite unprecedented advances in treatment of atherosclerotic cardiovascular disease, it remains the leading cause of death and disability worldwide. Treatment of major traditional risk factors, including low-density lipoprotein-cholesterol, serves as the foundation of atherosclerotic risk reduction. However, there remains a significant residual risk of cardiovascular events despite optimal risk factor management. Beyond traditional risk factors, other drivers of residual risk have come to the forefront, including inflammatory, pro-thrombotic, and metabolic pathways that contribute to recurrent events and are often unrecognized and not addressed in clinical practice. This review will explore the evidence linking these pathways to atherosclerotic cardiovascular disease and potential future therapeutic options to attenuate residual cardiovascular risk conferred by these pathways.

引用

页数：11

共 110 条

[31] Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease [J].

Jepsen, Anne-Marie K. ;

Langsted, Anne ;

Varbo, Anette ;

Bang, Lia E. ;

Kamstrup, Pia R. ;

Nordestgaard, Borge G. .

CLINICAL CHEMISTRY, 2016, 62 (04) :593-604

[32] Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis [J].

Jun, Min ;

Foote, Celine ;

Lv, Jicheng ;

Neal, Bruce ;

Patel, Anushka ;

Nicholls, Stephen J. ;

Grobbee, Diederick E. ;

Cass, Alan ;

Chalmers, John ;

Perkovic, Vlado .

LANCET, 2010, 375 (9729) :1875-1884

[33] Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population [J].

Kamstrup, Pia R. ;

Benn, Marianne ;

Tybjaerg-Hansen, Anne ;

Nordestgaard, Borge G. .

CIRCULATION, 2008, 117 (02) :176-184

[34] Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study [J].

Kaplan, Hillard ;

Thompson, Randall C. ;

Trumble, Benjamin C. ;

Wann, L. Samuel ;

Allam, Adel H. ;

Beheim, Bret ;

Frohlich, Bruno ;

Sutherland, M. Linda ;

Sutherland, James D. ;

Stieglitz, Jonathan ;

Rodriguez, Daniel Eid ;

Michalik, David E. ;

Rowan, Chris J. ;

Lombardi, P. ;

Bedi, Ram ;

Garcia, Angela R. ;

Min, James K. ;

Narula, Jagat ;

Finch, Caleb E. ;

Gurven, Michael ;

Thomas, Gregory S. .

LANCET, 2017, 389 (10080) :1730-1739

[35]

Kearney PM, 2008, LANCET, V371, P117, DOI 10.1016/S0140-6736(08)60104-X

[36] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[37] Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) [J].

Khera, Amit V. ;

Everett, Brendan M. ;

Caulfield, Michael P. ;

Hantash, Feras M. ;

Wohlgemuth, Jay ;

Ridker, Paul M. ;

Mora, Samia .

CIRCULATION, 2014, 129 (06) :635-642

[38] High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions The CANHEART Study [J].

Ko, Dennis T. ;

Alter, David A. ;

Guo, Helen ;

Koh, Maria ;

Lau, Geoffrey ;

Austin, Peter C. ;

Booth, Gillian L. ;

Hogg, William ;

Jackevicius, Cynthia A. ;

Lee, Douglas S. ;

Wijeysundera, Harindra C. ;

Wilkins, John T. ;

Tu, Jack V. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (19) :2073-2083

[39] LIPOPROTEIN-LP(A) AND THE RISK FOR MYOCARDIAL-INFARCTION [J].

KOSTNER, GM ;

AVOGARO, P ;

CAZZOLATO, G ;

MARTH, E ;

BITTOLOBON, G ;

QUNICI, GB .

ATHEROSCLEROSIS, 1981, 38 (1-2) :51-61

[40] Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes A Mendelian Randomization Analysis [J].

Lamina, Claudia ;

Kronenberg, Florian ;

Mack, Salome ;

Coassin, Stefan ;

Rueedi, Rico ;

Yousri, Noha A. ;

Seppala, Ilkka ;

Gieger, Christian ;

Schonherr, Sebastian ;

Forer, Lukas ;

Erhart, Gertraud ;

Marques-Vidal, Pedro ;

Ried, Janina S. ;

Waeber, Gerard ;

Bergmann, Sven ;

Daehnhardt, Doreen ;

Stoeckl, Andrea ;

Raitakari, Olli T. ;

Kahonen, Mika ;

Peters, Annette ;

Meitinger, Thomas ;

Strauch, Konstantin ;

Kedenko, Ludmilla ;

Paulweber, Bernhard ;

Lehtimaki, Terho ;

Hunt, Steven C. ;

Vollenweider, Peter ;

Lamina, Claudia ;

Kronenberg, Florian .

JAMA CARDIOLOGY, 2019, 4 (06) :575-579

← 1 2 3 4 5 6 7 8 9 10 →